AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Neuroscience Portfolio — U.S. net revenues by Year
Neuroscience Portfolio — U.S. net revenues ($M) ($M)
AbbVie Neuroscience Portfolio — U.S. net revenues: $9,340M in FY2025, up 18.1% from a year earlier.
Where the FY2025 figure comes from
“|| Neuroscience | 9,340 | 1,427 | 10,767 | 18.1 | 30.7 | 19.6 | 29.3 | 19.4”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuroscience Portfolio — U.S. net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9,340 | +18.1% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 7,907 | +16.5% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 6,790 | +19.5% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 5,681 | +12.3% | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 5,061 | +76.8% | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | 2,862 | – | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
Breakdown
What makes up neuroscience Portfolio — U.S. net revenues
Cite this data
StockData. (2026). AbbVie Neuroscience Portfolio — U.S. net revenues ($M), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta-neuro-us
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.